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Abstract: The pathway of the receptor activator of the nuclear factor κB ligand (RANKL), 
RANK and osteoprotegerin (OPG) plays a central role in coupling bone formation and resorp-
tion during normal bone turnover and in a wide spectrum of diseases characterized by disturbed 
bone remodeling, increased bone resorption and bone destruction (osteoporosis, Paget’s dis-
ease of bone, rheumatoid arthritis [RA], metastatic bone disease). Clinical trials indicate that 
denosumab, a RANKL-specific recombinant humanized monoclonal antibody, is effective 
in suppressing bone resorption, resulting in increase in bone mineral density (BMD) in post-
menopausal women with low BMD, and has the potential to prevent progression of erosions in 
RA and of skeletal-related events in metastatic bone disease. The effects on fracture reduction 
in postmenopausal osteoporosis are awaited from the recently finished FREEDOM study. In 
clinical trials with denosumab, overall adverse events were similar to placebo or comparators, 
indicating a favorable safety profile in these diseases, which until now have been available up 
to 4 years, but data on long-term safety will be needed.
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Introduction
Bone’s resistance to fracture is determined by its structural and material characteristics, 
which are determined by life-long remodeling of bone by osteoclastic bone resorption 
and osteoblastic bone formation.1 The discovery of the receptor activator of nuclear 
factor κB ligand (RANKL), osteoprotegerin (OPG) and RANK is a major contribution 
in our understanding of the balanced coupling in space, time and quantity between 
bone formation and resorption and its disconnection in several bone diseases character-
ized by increased bone resorption and destruction, such as osteoporosis, rheumatoid 
arthritis (RA), Paget’s disease of bone and metastatic bone disease.2
In this review I focus on the clinical relevance of the RANKL/RANK/OPG pathway 
in health and disease and the effect of denosumab, a recombinant fully humanized 
monoclonal RANKL-specific antibody that inhibits bone resorption, in a wide spec-
trum of diseases. For an extensive list of references on preclinical studies, the reader 
is referred to a recent in-depth review.2
The RANKL/OPG/RANK pathway: the discovery 
of how bone formation and resorption are coupled
For many decades, it has been known that bone resorption and formation in healthy adults 
are coupled in space, time and quantity,3 but the exact mechanisms behind this coupling 
remained for a long time obscure.4 In the late 1990s, the first component identified for a Clinical Interventions in Aging 2009:4 242
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novel pathway regulating bone remodeling was OPG.5,6 OPG 
was discovered by sequencing random clones from a cDNA 
library and its gene was shown to encode a novel member of the 
tumor necrosing factor (TNF) receptor family. Overexpression 
of the OPG gene in mice resulted in high bone mass and marked 
reduction in osteoclast number and activity, while OPG knock-
out (KO) mice had low BMD, increased numbers of osteoclasts, 
had more woven bone, and developed spontaneous fractures.7 
OPG is a decoy receptor for RANKL and in this way decreases 
bone resorption. OPG is produced by osteoblasts, endothelial 
cells, vascular smooth muscle and other cells.
Already in 1980 it was suggested that osteoblasts might 
be involved in osteoclastogenesis.8 The nature of this hypoth-
esized ‘osteoclast activating factor’ remained elusive, until 
1998, when several laboratories independently identified 
RANKL as a new member of the TNF family of transmem-
brane and soluble ligands that could bind to OPG9,10 and which 
was one year earlier identified as a product of activated T cells 
that promotes dentritic cell survival and co-stimulation.11 
RANKL KO mice have high bone mass and virtually no osteo-
clasts. RANKL binds to RANK and is in this way involved 
in numerous aspects of osteoclast differentiation and function 
(fusion, differentiation, attachment to bone, activation and 
survival). In most instances RANKL relies on macrophage-
colony stimulating factor (M-CSF) as a cofactor for osteoclast 
differentiation, but RANKL can stimulate osteoclastogenesis 
and bone resorption in mice lacking functional M-CSF and 
no factor or combination of factors have been shown to be 
capable of restoring bone resorption when RANKL is absent, 
indicating the dominant role of RANKL in the regulation of 
bone resorption.2 RANKL is produced by cells of the oste-
oblastic lineage and by activated T cells.
RANK is a cell membrane receptor of the TNF family to 
which RANKL is bound and is found on dendritic cells and 
cells of the osteoclast lineage. RANK KO in mice results in 
the same phenotype as RANKL KO with high bone mass 
and virtually no osteoclasts.
The activation of RANK in osteoclasts results in activa-
tion of several intracellular signal transduction pathways, 
which bind the nuclear factor κB (NFκB). After ubiquitina-
tion of signal transducers (which results in their degradation 
by proteasomes), NFκB is released, so that it can translocate 
to the nucleus, where it upregulates cofactors that induce 
osteoclastogenic gene transcription (Figure 1).
The many available data suggest that the RANKL:OPG 
ratio represents an important determinant of bone resorption.2 
Numerous growth factors, hormones, cytokines and drugs 
that influence bone turnover have been shown to influence 
the expression of RANKL and OPG.2 The RANKL:OPG 
ratio is decreased by estrogens and increased by glucocor-
ticoids (GC), parathyroid hormone (PTH), PTH-related 
protein (PTHrP) and prostaglandins. Other molecules and 
agents that regulate RANKL and/or OPG and that are 
proresorptive include interleukin-1 (IL-1), IL-17, TNF-α, 
1,25-dihydroxyvitamin D and bone morphogenetic protein 2 
(BMP-2). Those which suppress osteoclastogenesis and regu-
late RANKL and/or OPG are IL-4, IL-13, interferon-γ 
(IFN-γ) and transforming growth factor-β (TGF-β).
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Figure 1 Free rANKL (ie, not bound by osteoprotegerin [OPG]) binds to the transmembrane rANK receptor, which upregulates intracellular signal transducers which are 
involved in cytoskeletal organization, cell motility, growth and survival, and some also bind NFκB. After ubiquitination, signal transducers are released from NFκB and degraded 
by proteasomes. NFκB can than migrate to the nucleus, were it upregulates transcriptional regulators that start osteoclastogenic gene transcription.2Clinical Interventions in Aging 2009:4 243
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OPG prevents the ability of proresorptive agents (IL-1, 
TNF-α, PTH, PTHrP, vitamin D) to increase bone resorption in 
mice.2 In RANK KO mice, IL-1 and TNF-α induced the appear-
ance of few if any osteoclasts with no evidence of bone resorp-
tion. TNF-α was shown to require very low ‘permissive’ levels 
of RANKL to stimulate osteoclasts. Thus, whereas TNF-α, 
IL-1 and other molecules have certain independent stimulatory 
effects on osteoclasts, the very existence of those osteoclasts 
remains dependent on RANKL/RANK signaling.2
The Wnt (wingless) signaling in osteoblasts is also a source 
of regulation of OPG. Ablation of the intracellular canonic sig-
naling pathway (β-catenin) in osteoblasts resulted in reduced 
OPG expression and bone loss, while its over expression 
resulted in increased OPG expression and high bone mass.12 
Ablation of osteocytes in mice increased bone resorption and 
the RANKL:OPG ratio.13 These observations have enabled to 
integrate the RANKL/RANK/OPG and Wnt signaling path-
ways in understanding normal and diseased bone.14
The RANKL/OPG/RANK pathway: 
its role in healthy bone turnover
The dominant physiological role of the RANKL/RANK/OPG 
pathway in the regulation of bone remodeling has been 
demonstrated in the above mentioned transgenic and KO 
mice models.
Injection of recombinant RANKL and OPG in mice 
induced a rapid and marked effect on bone turnover markers 
(BTM) and number of osteoclasts. One RANKL injection 
stimulated bone resorption within 1 hour.15 One OPG injec-
tion resulted in decreased BTM within 2 hours and a 50% to 
60% reduction in osteoclast numbers within 12 to 24 hours 
with a long lasting effect which is fully reversible after 1 to 
2 months, and which is the result of the long half life and the 
time required to generate new osteoclasts once the drug is 
cleared.16 In small animals, OPG had positive effects on bone 
mineral content (BMC) and BMD, trabecular bone volume 
(TBV) and bone strength.2 Similar positive effects were found 
with denosumab in monkeys. Bone strength parameters were 
strongly correlated with bone mass parameters, suggesting 
that RANKL inhibition improved bone strength primarily 
by increasing bone mass and that bone formed during anti-
RANKL treatment has normal material properties. RANKL 
inhibition in animals also prevented bone loss after ovariec-
tomy, orchidectomy, GC use, and disuse.2
The discovery of the RANKL/OPG/RANK pathway and 
these experiments have elucidated our understanding of cel-
lular and mechanisms of bone remodeling. During normal bone 
remodeling, osteoclast precursors derived from the circulation 
or bone marrow develop a RANKL/RANK driven cell contact 
with osteoblasts. This enables osteoclast precursors to differen-
tiate to mature osteoclasts and activates their bone resorption 
capacity by attaching to bone, polarizing, becoming mobile, 
expressing the calcitonin receptor and tartrate-resistant alkaline 
phosphatase (TRAP), producing H+ by carbonic anhydrase II, 
secretion of H+ by the osteoclast-specific vacuolar ATP-ase 
pump and Cl− by the Cl− channel to form HCL that degrades 
bone mineral, lysosomal release of cathepsin-K and matrix 
metalloproteinases (MMPs) that degrade bone matrix proteins, 
and by contributing to osteoclast mobility and survival.17
Non-osseous effects of the RANKL/
OPG/RANK pathway
The above-mentioned OPG, RANKL and RANK KO animal 
models revealed significant extraskeletal manifestations with 
regard to vascular calcifications, the immune system and 
mammary gland development.
OPG KO animals developed medial calcification of the 
aorta and renal arteries,7 which could be prevented by trans-
genic over expression of soluble OPG. RANKL and OPG 
have been identified in human atherosclerotic plaques.18 The 
mechanism by which OPG could serve a protective role in 
vascular disease is unclear. Experiments in animal models of 
atherosclerosis indicate that the prevention of vascular calcifi-
cation is probably related to the suppression of bone resorption, 
with neutral effects on existing atherosclerotic changes.2
RANK and RANKL KO results in lymph node agenesis, 
indicating the role of the RANKL/RANK/OPG pathway devel-
opment and function of the immune system.2 As mentioned 
earlier, activated T cells produce RANKL and thereby regu-
late the function and survival of dendritic cells.11 However, 
RANKL inhibition did not lead to dendritic cell suppression, 
probably due to the central role of CD40 cross-talk between 
T cells and dendritic cells, which compensates for the total 
absence of RANKL/RANK in KO mice.2 RANKL and RANK 
are found in bone erosions of RA, rendering RANKL a pos-
sible target to prevent bone erosions in RA.
RANKL/RANK KO mice have a defect in mammary 
gland development during pregnancy and lactation.2 However, 
OPG transgenic mice did not show failure of lactation, while 
bone resorption was inhibited.2
The RANKL/OPG/RANK pathway 
in osteolytic and destructive bone 
diseases
The RANKL/OPG/RANK pathway plays a crucial and 
consistent role in a wide spectrum of diseases of bone Clinical Interventions in Aging 2009:4 244
Geusens Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
characterized by increased bone resorption, disturbed 
coupling between bone formation and resorption, and bone 
destruction.
Mutations of the genes for RANKL, OPG and intracellular 
signal transducers of NFκB have been identified in diseases 
characterized by focal disturbed bone remodeling, such 
as juvenile and classical Paget’s disease of bone, familial 
expansile osteolysis, expansile skeletal hyperphosphatasia 
and inclusion body myopathy combined with Paget’s disease 
and frontotemporal demantion (IBMPFD).19
Rheumatoid arthritis (RA) is characterized by joint 
inflammation and bone erosions, periarticular and general-
ized bone loss. Bone erosions were already described in 1878 
as ‘caries of the joints,’20 but only during the last decades it 
has been shown that these erosions contain multinucleated 
cells which were identified as osteoclasts.21–23 Animal models 
of RA (collagen-induced arthritis (CIA), adjuvant-induced 
arthritis (AIA) and TNF-mediated arthritis) indicated 
early upregulation of RANKL and suppression of OPG in 
inflamed joints. RANKL KO and OPG prevented formation 
of erosions, without effect on inflammation.2 This indicates 
that bone destruction and inflammation can be dissociated 
on the basis of specific inhibition of the RANKL/RANK 
pathway. OPG also prevented periarticular and generalized 
bone loss in such animal models2 and preserved cartilage in 
several arthritic animal models.2 RANKL, RANK and OPG 
are expressed in human articular cartilage, but their functional 
roles have not been clearly demonstrated, and RANK is 
probably inactive in chondrocytes.2 A likely mechanism for 
chondroprotection by OPG is to preserve subchondral bone 
against subchondral osteoclast invasion.2
More than 100 years ago it had been observed that 
bone was a fertile soil for the localization and growth of 
particular types of cancer cells.24 Recently it has become 
clear that there is a bidirectional communication between 
tumor cells and bone cells, resulting in a vicious circle of 
bone destruction and tumor growth.2,25,26 In metastatic bone 
disease, cancer cells are able to increase the RANKL: OPG 
ratio directly or by the help of T-cells, osteoblast/stromal 
cells and endothelial cells, along with the production of other 
osteoclast mediators such as PTHrP. This stimulates osteo-
clasts to remove bone, enabling cancer cells to make space 
for further growth within bone,25,26 and releasing growth 
factors from bone that further stimulate tumor growth. 
Multiple myeloma cells are even more destructive for bone, 
as they release not only RANKL, but also dickkopff (DKK), 
which suppresses bone formation, ampliflying in this way 
room for tumor growth.26
Denosumab: the effect of RANKL 
inhibition in osteoporosis, RA 
and metastatic bone disease
Denosumab is a fully human monoclonal antibody with 
a high affinity and specificity for RANKL and binds and 
neutralizes the activity of human RANKL in a similar fashion 
to the action of OPG.2 Denosumab does not cross-react with 
TNF-α, TNF-β, TNF-related apoptosis-inducing ligand 
(TRAIL), or CD40 ligand.
Postmenopausal osteoporosis
The first clinical study on RANKL inhibition was performed 
in postmenopausal women with BMD-osteoporosis using 
OPG bound to the constant fragment (Fc) of human IgG1 
(Fc-OPG), which showed a dose-dependent decrease of 
markers of bone resorption within 4 days with a maximum 
decrease of 80% with the highest dose and lasting 45 days, 
without changes in markers of bone formation.27 However, 
Fc-OPG was not further studied because denosumab was 
superior in reducing bone resorption at lower dose and with 
longer duration,24 antibodies to Fc-OPG could be raised24 and 
because of the concern that Fc-OPG could bind to TRAIL, 
which could inhibit its role in tumor surveillance.28
Denosumab has been studied in postmenopausal women 
in the context of its effect on bone remodeling, BMD, param-
eters of bone strength in the hip region, and safety.
In a randomized, placebo-controlled phase-1 study in 
49 healthy postmenopausal women, a single SC injection of 
denosumab caused a dose-dependent rapid (within 12 hours), 
profound (up to 84%) and sustained (up to 6 months) decrease 
in bone resorption (reflected by urinary N-telopeptide (NTX)) 
and was well tolerated.28 Bone formation (as reflected by 
bone-specific alkaline phosphatase (BALP)) did not decrease 
remarkably until after 1 month, indicating that the effect of 
denosumab is primarily antiresorptive. Intact PTH levels 
increased up to 3-fold after 4 days, but returned towards 
baseline with follow-up. This study indicated that denosumab 
effectively decreases bone resorption in humans and that long 
intervals between doses of denosumab might be possible.
Efficacy and safety of denosumab were evaluated in 
a randomized, placebo-controlled, dose-ranging phase 2 
study in 412 postmenopausal women with low BMD in the 
spine or femur and included a group of patients treated with 
open-label alendronate 70 mg/week.29 Denosumab (at a dose 
of 6, 14 or 30 mg every 3 months or 14, 60, 100 or 210 mg 
every 6 months over a period of 12 months) resulted in a 
rapid and sustained effect on BTM and a rapid increase in Clinical Interventions in Aging 2009:4 245
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BMD in the spine, hip and distal radius, which was superior 
to placebo and similar or greater (for changes in BMD in 
the total hip and in the distal radius and in markers of bone 
resorption) than with weekly 70 mg of alendronate (Figure 2). 
These changes were sustained in an extension study over 
24 months (Figure 3).30 Adverse events (AE) and serious 
AE (SAEs) were similar in character and percentage with 
denosumab compared with placebo. In terms of increase 
in BMD, the dose of 30 mg/3 months and 60 mg/6 months 
appeared optimal.
In a post hoc analysis of this study in a subgroup of 
116 patients treated with denosumab 60 mg every 6 months, 
weekly alendronate 70 mg or placebo, structural geometry of 
the hip was evaluated on DXA images, and derived strength 
indices were calculated, including bone cross-sectional area, 
section modulus and buckling ratio.31 At 12 and 24 months 
denosumab and alendronate improved these parameters 
compared with placebo. Denosumab effects were greater 
than alendronate at the intertrochanteric and femoral shaft 
sites. These results suggested that denosumab treatment may 
lead to improved bone biomechanical properties, similar or 
greater than with weekly alendronate.
The phase 2 study was continued for an additional 
24 months to study the long-term efficacy and safety of 
denosumab and the effects of discontinuing and restarting 
different doses of denosumab treatment.32 With continuous 
treatment, denosumab led to further gains in BMD at the 
lumbar spine, total hip and distal 1/3 radius and sustained 
reduction in BTM throughout the course of the study. The 
effects on BTM were fully reversible with discontinuation 
and restored with subsequent retreatment (Figure 4).
In a double-blind phase 3 study, including 1180 
postmenopausal women with low BMD (T-score  2.0 
in the lumbar spine or total hip), the efficacy and safety of 
denosumab 60 mg every 6 months and alendronate 70 mg 
weekly during 12 months treatment were compared.33 At 
the total hip, denosumab significantly increased BMD 
compared to alendronate (2.5% versus 2.6%, p  0.0001). 
Furthermore, significantly greater increases in BMD were 
observed with denosumab at all measured skeletal sites 
(12-month treatment difference: 1.1% in the lumbar spine, 
0.6% in the femoral neck, 1.0% in the trochanter and 0.6% 
in the 1/3 radius; p  0.001 at all sites). Compared to 
alendronate, treatment with denosumab resulted in greater 
reductions in BTM (serum C-telopeptide-1 [sCTX1] for bone 
resorption and P1NP for bone formation) at each time point 
assessed through month 9 for sCTX1 and month 12 for P1NP. 
Maximum reduction of P1NP in the alendronate group was 
reached at month 3 and remained constant throughout the 
study (Figure 5). In contrast, maximal reduction of sCTX1 in 
the denosumab group was observed at 1 month, with attenu-
ated reduction in sCTX1 at the end of the 6-month dosing 
interval. AEs were similar for denosumab- and alendronate-
treated subjects. SAEs were similar between denosumab and 
alendronate for infections (1.5% versus 1.0%, p = 0.61) and 
malignant neoplasm (1.0% versus 0.9%, p = 1.00).
Similar changes in BMD and BTM were reported in a 
2-year randomized, double-blind, placebo-controlled study 
in 332 postmenopausal women with BMD-osteopenia treated 
with the same dose of denosumab (60 mg every 6 month).34 
SEAs for infections were significantly higher in the deno-
sumab group (4.9%) then with placebo (0.6%, p  0.05) and 
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similar for neoplasm (2.4% with denosumab versus 0.6% 
with placebo, p = 0.215).
Meanwhile, the pivotal fracture trial (Fracture REduction 
Evaluation of Denosumab in Osteoporosis every 6 Months, 
the ‘FREEDOM’ study) with fracture reduction as a primary 
endpoint has been accomplished in 7,808 postmenopausal 
women with BMD-osteoporosis,35 and a peer-reviewed 
publication is expected soon.
rheumatoid arthritis
In animal models of arthritis (CIA and AIA) RANKL 
expression has been demonstrated within 1 to 14 days of the 
appearance of joint inflammation.2 OPG fully prevented the 
occurrence of bone erosions, without effect on cartilage loss 
and inflammation. In patients with RA, RANKL expression 
has been documented in erosions. Furthermore, baseline 
serum levels of the RANKL:OPG ratio predicted future joint 
damage independent of other predictors of joint damage in 
patients with early untreated RA.36
In a placebo-controlled study in 227 patients with RA 
taking methotrexate, 71 were treated with denosumab 60 mg, 
72 with 180 mg denosumab and 75 had placebo injections 
every 6 months during 12 months.37 At 6 months, the increase 
in MRI erosion score from baseline was significant lower 
in the 180-mg denosumab group than in the placebo group 
(0.06 versus 1.75, p = 0.007). A significant difference in 
Placebo
60 mg Q6M
Months
P
e
r
c
e
n
t
 
c
h
a
n
g
e
(
L
S
 
M
e
a
n
 
±
 
S
E
)
–4
–2
0
2
4
6
8
10
12
14
0 3 6 12 18 24 36 48
10.3
9.0
Continued Treatment at 
60 mg Q6M
–2.4 –1.8
7.2
–1.3
Figure 3 effect of 4 years of denosumab every 6 months on lumbar spine (LS) bone mineral density.   Adapted from J Bone Miner Res. 2007;22:1832–1841,30 with permission 
of the American Society for Bone and Mineral research.
Re-treatment
60 mg Q6M
–2.4 –1.8
Discontinued
Treatment
9.0
1.9
0 3 6 12 18 24 36 48
–6
–2
0
2
4
6
8
10
12
14
–4
8.8
–1.3
–6
–4
–2
0
2
4
6
8
0 3 6 12 18 24 36 48
Re-treatment
60 mg Q6M
Discontinued
Treatment
–2.8
–3.5
–1.2
3.9
5.0
–1.9
Months Months
P
e
r
c
e
n
t
 
c
h
a
n
g
e
(
L
S
 
M
e
a
n
 
±
 
S
E
)
 
Lumbar spine Total hip
Placebo
30 mg Q3M
Figure 4 effect of denosumab re-treatment and changes to lumbar spine (LS) and total hip bone mineral density.  reproduced with permission from Miller PD, Bolognese MA, 
Lewiecki eM, et al. Amg Bone Loss Study Group. effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, 
discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial. Bone. 2008;43(2):222–229.32 Copyright © 2008 elsevier.Clinical Interventions in Aging 2009:4 247
Denosumab for postmenopausal osteoporosis Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
the modified Sharp erosion score was observed as early as 
6 months in the 180-mg denosumab group (0.05) compared 
with placebo (0.59, p = 0.019), and at 12 months, both the 
60-mg (0.33) and 180-mg (0.19) denosumab groups were 
significantly different from the placebo group (1.34, p = 0.012 
and p = 0.007, respectively). Denosumab caused sustained 
suppression of BTM. There was no evidence of an effect of 
denosumab on joint space narrowing or measure of disease 
activity. Rates of AE and SAE were comparable between the 
denosumab and placebo groups.
Metastatic bone disease
Denosumab has been studied in patients with breast and 
prostate cancer and multiple myeloma.38–42 Denosumab was 
well tolerated and decreased markers of bone resorption, even 
in patients previously resistant to bisphosphonates (BP) in 
reducing bone resorption.
In patients with multiple myeloma (n = 25) or bone 
metastases from breast cancer (n = 29), a single SC dose 
of denosumab reduced bone resorption for at least 84 days 
and was well tolerated.38 The decrease in bone turnover 
markers was similar in magnitude but more sustained than 
with IV pamidronate.
In 255 women with breast cancer-related bone metas-
tases, subcutaneous denosumab was similar to IV BP in 
suppressing bone turnover and reducing skeletal-related 
events risk.39 The safety profile was consistent with an 
advanced breast cancer population receiving systemic 
therapy.
In women with non-metastatic breast cancer and low bone 
mass who were receiving adjuvant aromatase inhibitor therapy, 
twice-yearly administration of denosumab significantly 
increased BMD over 24 months at trabecular and cortical bone, 
with overall AE rates similar to those of placebo.40
A next study evaluated the effects of denosumab in 
IV BP-naïve patients with breast cancer-related bone 
metastases. Denosumab suppressed bone turnover and 
seemed to reduce SRE risk similarly to IV BPs, with a safety 
profile consistent with an advanced cancer population receiv-
ing systemic therapy.41
Safety of denosumab
Fracture repair
In studies of the effect of RANKL inhibition on fracture 
repair, high doses of OPG given to rats at the time of frac-
ture did not influence the formation of a normal fracture 
callus, but delayed callus remodeling.42 In an animal study 
of transverse femur fracture healing, alendronate and deno-
sumab delayed the removal of cartilage and the remodeling 
of the fracture callus.43,44 However, this did not diminish 
the mechanical integrity of the healing fractures in mice 
receiving these treatments. In contrast, strength and stiffness 
were enhanced in these treatment groups when compared to 
control bones.44
Immunosuppression
As mentioned earlier, the RANKL/OPG/RANK pathway is 
involved in the development of the immune system. Therefore, 
Figure 5 effect of denusomab vs alendronate head to head trial on bone markers. reproduced from J Bone Miner Res. 2009;24:153–161,33 with permission of the American 
Society for Bone and Mineral research.
Notes: asignificantly different from alendronate, p  0.0001.
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safety issues about infection and neoplasm deserve special 
attention when therapeutically interfering with this pathway.2
OPG did not alter cellular or humoral immunity, or render 
mice more susceptible to bacterial challenge at doses that 
inhibited bone resorption.2 Furthermore, OPG prevented 
bone erosions and bone loss without affecting the degree of 
inflammation.2
In the published clinical trials on osteoporosis, no sig-
nificant differences in infections reported as SAE were found 
between denosumab, placebo and alendronate,28–33 except in 
one study in 332 subjects with osteopenia (4.9% with deno-
sumab versus 0.6% with placebo, p  0.05).34 The six SAEs of 
infections associated with denosumab in the 24-month phase-2 
study were common community-acquired infections that were 
successfully treated with standard antibiotics during uncom-
plicated hospital courses.32 The rate of infections remained 
unchanged from year 1 to year 2 in the denosumab group.32
No significant differences in neoplasms reported as SAE 
were found between denosumab, placebo and BP-treated 
patients.38–41
Osteonecrosis of the jaw
Osteonecrosis of the jaw (ONJ) is a potential side effect of 
BPs, especially when given IV in high doses.45 The incidence 
of ONJ in patients using oral BPs for osteoporosis is low, and 
associated with other risks for ONJ, such as infection, and 
possibly other, not yet well defined risks and co-morbidities.45 
Up until now, ONJ has not been reported in the clinical trials 
with denosumab.
Comparison of denosumab 
with bisphosphonates
The effect of RANKL inhibition is quite unique among 
antiresorptive agents. RANKL inhibition differed from the 
effects of BPs on bone in several aspects.
First, OPG, at least in animal models, does not damage 
the osteoclasts but decreases their number while BPs inhibit 
the function of osteoclasts by damaging the cytoskeleton, 
without affecting or even increasing the number of osteo-
clasts.29,46,47 Second, denosumab resulted in a quicker decrease 
in markers of bone resorption than alendronate.29 Third, this 
effect on bone resorption was more pronounced than with 
alendronate.29 Fourth, the effect of denosumab is completely 
reversible and cleared over a relatively short period of time, 
in contrast to the long term effects of BPs.28 The complete 
reversibility of bone remodeling after denosumab could result 
in a quicker response of changes in BMD than BPs when 
anabolic agents such as PTH are subsequently given.48 Fifth, 
denosumab effects were greater than alendronate on BMD and 
on strength indices derived from hip geometry evaluated by 
DXA at the intertrochanteric and femoral shaft sites.31 Sixth, 
patient preference could be different between denosumab 60 
mg every 6 months and weekly bisphosphonates.49 Lastly, 
denosumab is the first anti-bone resorbing agent that has been 
shown to halt bone erosions in RA.37 Although bisphospho-
nates are successful in preventing erosions in animal models 
of inflammatory arthritis, support from studies in humans is 
lacking,50–52 with the exception of some effect of zoledronate 
that showed slowing in the number of erosions.53
Conclusions
The RANKL/RANK/OPG pathway plays a central role 
in coupling bone formation and resorption during normal 
bone turnover and a central and common role in a wide 
spectrum of diseases characterized by disturbed bone 
remodeling and increased bone resorption and destruction 
(osteoporosis, Paget’s disease of bone, RA, metastatic bone 
disease). Clinical trials in postmenopausal women indicate 
that denosumab, a RANKL-specific recombinant human-
ized monoclonal antibody, is effective in suppressing bone 
resorption resulting in increase in BMD in osteoporosis, and 
has the potential to prevent progression of erosions in RA 
and of skeletal-related events in metastatic bone disease. The 
effects on fracture reduction in osteoporosis are awaited from 
the recently finished FREEDOM study. In clinical trials with 
denosumab, overall AEs and SAEs were similar to placebo, 
indicating a favorable safety profile in these diseases, but 
data on long-term safety will be needed.
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